174727-69-6

Basic information

• Product Name: 2-[1-(2,5-Dimethyl-benzyl)-5-methoxy-1H-indol-3-yl]-ethylamine
• CAS NO: 174727-69-6
• Molecular Weight: 308.423
• Mol File: 174727-69-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-[1-(2,5-Dimethyl-benzyl)-5-methoxy-1H-indol-3-yl]-ethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[1-(2,5-Dimethyl-benzyl)-5-methoxy-1H-indol-3-yl]-ethylamine(174727-69-6)
• EPA Substance Registry System: 2-[1-(2,5-Dimethyl-benzyl)-5-methoxy-1H-indol-3-yl]-ethylamine(174727-69-6)

Safety Data

• Hazardous Substances Data: 174727-69-6(Hazardous Substances Data)

Upstream product

• 824-45-3 2,5-dimethylbenzyl chloride 
• 66-83-1 5-methoxytryptamine hydrochloride 
• 52648-13-2 5-methoxytryptamine-2-carboxylic acid 
• 17952-87-3 6-methoxy-2,3,4,9-tetrahydro-β-carbolin-1-one 
• 608-07-1 2-(5-methoxyindol-3-yl)ethylamine 

Downstream Products

• 1053644-75-9 (3aS,4S,6R,6aR)-6-(6-{2-[1-(2,5-Dimethyl-benzyl)-5-methoxy-1H-indol-3-yl]-ethylamino}-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid cyclopropylamide 

Relevant articles and documents

N6-Substituted Adenosine Receptor Agonists. Synthesis and Pharmacological Activity as Potent Antinociceptive Agents

Novel N6-(indol-3-yl)alkyl derivatives of adenosine were synthesized.The adenosine receptor affinity and the antinociceptive activity of these compounds were assessed in binding studies and the phenylbenzoquinone-induced writhing test.Most of these analogues exhibited a potent analgesic activity without side effects.Among them, compound 3c (UP 202-32) bound to A1 (Ki = 110 nM) and A2 (Ki = 350 nM) adenosine receptors in a specific manner since it did not interact with many other receptors, especially opioid binding sites.The antinociceptive activity in the phenylbenzoquinone assay (ED50 = 3.3 mg/kg po) was antagonized by 8-cyclopentyltheophylline, suggesting that an adenosinergic mechanism underlies the analgesic activity observed with this compound.The data obtained with these new N6-substituted adenosine receptor agonists emphasize the interest of such compounds in the treatment of pain.